CA3170434A1 - Anti-glycan antibodies and uses thereof - Google Patents

Anti-glycan antibodies and uses thereof Download PDF

Info

Publication number
CA3170434A1
CA3170434A1 CA3170434A CA3170434A CA3170434A1 CA 3170434 A1 CA3170434 A1 CA 3170434A1 CA 3170434 A CA3170434 A CA 3170434A CA 3170434 A CA3170434 A CA 3170434A CA 3170434 A1 CA3170434 A1 CA 3170434A1
Authority
CA
Canada
Prior art keywords
seq
antibody
sequence
antigen
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3170434A
Other languages
English (en)
French (fr)
Inventor
Leonard Presta
Tony Liang
Jennifer Cheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ptm Therapeutics Inc
Original Assignee
Ptm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptm Therapeutics Inc filed Critical Ptm Therapeutics Inc
Publication of CA3170434A1 publication Critical patent/CA3170434A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3170434A 2020-03-17 2021-03-16 Anti-glycan antibodies and uses thereof Pending CA3170434A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062990927P 2020-03-17 2020-03-17
US62/990,927 2020-03-17
US202063037374P 2020-06-10 2020-06-10
US63/037,374 2020-06-10
US202063074956P 2020-09-04 2020-09-04
US63/074,956 2020-09-04
PCT/US2021/022627 WO2021188591A1 (en) 2020-03-17 2021-03-16 Anti-glycan antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CA3170434A1 true CA3170434A1 (en) 2021-09-23

Family

ID=75581605

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3170434A Pending CA3170434A1 (en) 2020-03-17 2021-03-16 Anti-glycan antibodies and uses thereof

Country Status (8)

Country Link
US (3) US11230608B2 (https=)
EP (1) EP4121460A1 (https=)
JP (2) JP2023518228A (https=)
KR (1) KR20220155333A (https=)
CN (1) CN115698082A (https=)
AU (1) AU2021237566A1 (https=)
CA (1) CA3170434A1 (https=)
WO (1) WO2021188591A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023133452A1 (en) * 2022-01-06 2023-07-13 PTM Therapeutics, Inc. Methods of treating solid tumors and compositions thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2013078425A1 (en) * 2011-11-22 2013-05-30 University Of Maryland, Baltimore Lambodies with high affinity and selectivity for glycans and uses therefor

Also Published As

Publication number Publication date
US20220340683A1 (en) 2022-10-27
US20210292432A1 (en) 2021-09-23
KR20220155333A (ko) 2022-11-22
JP2023518228A (ja) 2023-04-28
WO2021188591A1 (en) 2021-09-23
AU2021237566A1 (en) 2022-09-29
CN115698082A (zh) 2023-02-03
EP4121460A1 (en) 2023-01-25
US11230608B2 (en) 2022-01-25
US20250034276A1 (en) 2025-01-30
JP2026031937A (ja) 2026-02-25

Similar Documents

Publication Publication Date Title
US20220135693A1 (en) Humanized anti-CCR7 receptor antibodies
TWI631957B (zh) 抗－ｉｌ－２３抗體
JP7013632B2 (ja) 自己免疫疾患を治療するための抗ｉｆｎａｒ１抗体
US20240117030A1 (en) Multispecific antibodies and uses thereof
JP2021510141A (ja) Ｉｇおよびｉｔｉｍドメインを持つｔ細胞免疫受容体（ｔｉｇｉｔ）に対する抗体およびその使用
US12435145B2 (en) B7-H4 antibody formulations
US11525005B2 (en) Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
TW201902915A (zh) 針對淋巴細胞活化基因-3（lag-3）之抗體藥劑及其用途
TW201909926A (zh) Ｂ７ｈ３抗體－藥物偶聯物及其醫藥用途
TW201641516A (zh) 抗-ｉｌ-２３抗體
JP2026050358A (ja) 治療用抗ｃｄ４０リガンド抗体
US20240317864A1 (en) B7-h4 antibody dosing regimens
JP7843824B2 (ja) 抗体および使用方法
JP2021513324A (ja) 自己免疫疾患およびがんを治療するための抗ｃｘｃｌ１３抗体
EP3647323A1 (en) Anti-gitr antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
JP2026031937A (ja) 抗グリカン抗体及びそれらの使用
KR20250044359A (ko) 항-ccr8 항체 및 사용 방법
US20190002549A1 (en) Anti-gm-csf antibodies and uses thereof
WO2024251257A1 (en) Anti-cd24 antibodies and uses thereof
WO2025042888A1 (en) Methods of treating digestive diseases and compositions thereof
WO2025206223A1 (ja) 抗ヒトクローディン１８．２抗体及びその使用
HK40098542A (zh) 抗SIRPα单克隆抗体及其用途
HK40094973A (zh) 抗SIRPα单克隆抗体及其用途
TW202444410A (zh) 一種治療系統性紅斑狼瘡的方法
HK40108974A (zh) 抗btla抗体及其在治疗癌症中的用途

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241220

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241220

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241220

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250221

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250221

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250221

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250225

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250317

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250317

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250317

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250429

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250512

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251211

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251211